Skip to main content

Table 1 Baseline characteristics of the study participants

From: Association of the location and initial degree of malignant central airway stenosis with the risk of severe restenosis after interventional bronchoscopy

Characteristics Value
Age (y), (mean ± SD) 66.6 ± 8.2
Male, n (%) 214 (91.8)
Smoking, n (%) 166 (71.2)
Coexisting disease, n (%)  
  COPD 21 (9.0)
  Hypertension 58 (24.9)
  Diabetes 11 (4.7)
Dyspnea index, n (%) 13 (2.5)
  0 42 (18.0)
  1 9 (3.9)
  2 27 (11.6)
  3 30 (12.9)
  4 125 (53.6)
Location of the lesion, n (%)  
  Trachea 34 (14.6)
  Left main bronchus 75 (32.2)
  Right main bronchus 78 (33.5)
  Right intermediate bronchus 46 (19.7)
Initial degree of MCAS, (mean ± SD, %) 76.9 ± 23.9
Post-intervention residual stenosis, (mean ± SD, %) 28.4 ± 17.3
Histological types, n (%)  
  Lung adenocarcinoma 5 (2.1)
  Lung squamous cell carcinoma 186 (79.8)
  SCLC 17 (7.3)
  Other* 25 (10.7)
Stent implantation, n (%) 56 (24.0)
Other treatments after intervention,** n (%)  
  0 50 (21.5)
  1 81 (34.8)
  ≥ 2 102 (43.8)
Severe restenosis, n (%) 92 (39.5)
  1. COPD chronic obstructive pulmonary disease, MCAS malignant central airway stenosis, SCLC small-cell lung carcinoma
  2. *Other histological types including adenoid cystic carcinoma, lymphoma, large cell neuroendocrine carcinoma, mesenchymal tumor, soft tissue sarcoma, and metastatic malignancies (esophageal cancer, gastric cancer, colorectal adenocarcinoma, and thyroid papillary carcinoma)
  3. **Other treatments including radiotherapy, chemotherapy, molecule-targeted therapy, and immunotherapy. 0, patients didn’t receive any other treatment after therapeutic bronchoscopy; 1, patients received one other treatment after therapeutic bronchoscopy; ≥2, patients received at least two other treatments after therapeutic bronchoscopy